Androstanolone enanthate

Androstanolone enanthate
Clinical data
Trade names	Anaboleen Depot
Other names	Stanolone enanthate; Dihydrotestosterone enanthate; DHT enanthate; Dihydrotestosterone heptanoate; DHTH; 5α-Androstan-17β-ol-3-one 17β-heptanoate
Routes of; administration	Intramuscular injection
Drug class	Androgen; Anabolic steroid; Androgen ester
Identifiers
	IUPAC name [(5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl] heptanoate;
CAS Number	33776-88-4;
PubChem CID	160230;
ChemSpider	140831;
UNII	UAQ3N36A25;
CompTox Dashboard (EPA)	DTXSID90955358 ;
Chemical and physical data
Formula	C26H42O3
Molar mass	402.619 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CCC(=O)C4)C)C;
	InChI InChI=1S/C26H42O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h18,20-23H,4-17H2,1-3H3/t18-,20-,21-,22-,23-,25-,26-/m0/s1; Key:DDYHAKNCTGGYOK-LVYWIKMTSA-N;

Androstanolone enanthate (brand name Anaboleen Depot), also known as stanolone enanthate or dihydrotestosterone heptanoate (DHTH), as well as 5α-androstan-17β-ol-3-one 17β-heptanoate, is a synthetic androgen and anabolic steroid and a dihydrotestosterone ester.^[1]^[2] It is used as an injectable and acts as a prodrug of androstanolone (stanolone, dihydrotestosterone, DHT). The drug has been studied in and found to be effective in the treatment of gynecomastia in boys and adult men.^[3]^[4]^[5] The pharmacology of androstanolone enanthate has been studied.^[6]^[7]

References

^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 640–. ISBN 978-1-4757-2085-3.
^ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 261–. ISBN 978-94-011-4439-1.
^ Swerdloff RS, Wang C (October 1998). "Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent". Bailliere's Clinical Endocrinology and Metabolism. 12 (3): 501–506. doi:10.1016/S0950-351X(98)80267-X. PMID 10332569.
^ Eberle AJ, Sparrow JT, Keenan BS (July 1986). "Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate". The Journal of Pediatrics. 109 (1): 144–149. doi:10.1016/s0022-3476(86)80596-0. PMID 3088241.
^ Swerdloff RS, Dudley RE, Page ST, Wang C, Salameh WA (June 2017). "Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels". Endocrine Reviews. 38 (3): 220–254. doi:10.1210/er.2016-1067. PMC 6459338. PMID 28472278.
^ Keenan BS, Eberle AJ, Sparrow JT, Greger NG, Panko WB (March 1987). "Dihydrotestosterone heptanoate: synthesis, pharmacokinetics, and effects on hypothalamic-pituitary-testicular function". The Journal of Clinical Endocrinology and Metabolism. 64 (3): 557–562. doi:10.1210/jcem-64-3-557. PMID 3546348.
^ Coutts SB, Kicman AT, Hurst DT, Cowan DA (November 1997). "Intramuscular administration of 5 alpha-dihydrotestosterone heptanoate: changes in urinary hormone profile". Clinical Chemistry. 43 (11): 2091–2098. doi:10.1093/clinchem/43.11.2091. PMID 9365393.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

This article about a steroid is a stub. You can help Wikipedia by expanding it.

[Elks2014-1] Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 640–. ISBN 978-1-4757-2085-3.

[MortonHall2012-2] Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 261–. ISBN 978-94-011-4439-1.

[SwerdloffWang1998-3] Swerdloff RS, Wang C (October 1998). "Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent". Bailliere's Clinical Endocrinology and Metabolism. 12 (3): 501–506. doi:10.1016/S0950-351X(98)80267-X. PMID 10332569.

[pmid3088241-4] Eberle AJ, Sparrow JT, Keenan BS (July 1986). "Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate". The Journal of Pediatrics. 109 (1): 144–149. doi:10.1016/s0022-3476(86)80596-0. PMID 3088241.

[SwerdloffDudley2017-5] Swerdloff RS, Dudley RE, Page ST, Wang C, Salameh WA (June 2017). "Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels". Endocrine Reviews. 38 (3): 220–254. doi:10.1210/er.2016-1067. PMC 6459338. PMID 28472278.

[KeenanEberle1987-6] Keenan BS, Eberle AJ, Sparrow JT, Greger NG, Panko WB (March 1987). "Dihydrotestosterone heptanoate: synthesis, pharmacokinetics, and effects on hypothalamic-pituitary-testicular function". The Journal of Clinical Endocrinology and Metabolism. 64 (3): 557–562. doi:10.1210/jcem-64-3-557. PMID 3546348.

[pmid9365393-7] Coutts SB, Kicman AT, Hurst DT, Cowan DA (November 1997). "Intramuscular administration of 5 alpha-dihydrotestosterone heptanoate: changes in urinary hormone profile". Clinical Chemistry. 43 (11): 2091–2098. doi:10.1093/clinchem/43.11.2091. PMID 9365393.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

See also

References